A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

As the population ages, the market for Alzheimer's and cognitive disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?

What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations?

With regulatory and reimbursement approvals becoming more difficult, the profile of orphan disorders is on the rise. Companies have now shown that premium pricing for orphan disorders can propagate a highly successful business model. What new treatments are on the horizon?

Session Chair: Jennifer King

Senior Director, Scientific Licensing and Business Development, Shire

Andrew Gengos

CEO, Neuraltus

Jay LichterCEO, Afraxis & Managing Director, Avalon Ventures

Steve Orndorff

CEO, Ariel Pharmaceuticals

Anthony Ignagni

CEO, Synapse Biomedical

4:30

New Business Models in Neurotechnology

With venture capital steering away from long term and risky investments, neurosoftware, neurofeedback, neuromarketing and other new business models represent far lower risk and faster times to market. What winning strategies are emerging in brain fitness, sleep management, neuroplasticity, and human performance?

Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and inlicensing? With cutbacks in internal neuropharma R&D can we expect more partnering deals? Which companies are active in outlicensing deprioritized programs? What are priority indications and requirements for licensing deals? Where are the opportunities for neurodevice partnerships and where are the major players focusing their attentions? With big pharma paying more attention to neurodiagnostics, what kinds of deals and partnerships can we expect in 2011?

Moderator: Christine de los Reyes

Managing Director, BiotechPartnering Solutions

Peter LandoVice President of Intellectual Property & Business Development, St. Jude Medical

In this session we will hear from companies on the cutting edge. Novel neurostimulation devices are being developed for new markets including sensory disorders, hypertension, obesity, sleep apnea, neuroimmunology and many others. New technology developed in other fields is yeilding benefits in neurodiagnostics. Exciting new platforms leveraging cutting edge techniques are being used for drug discovery. Don't miss this preview of next generation products and companies.

Schizophrenia, anxiety, depression, addiction and other psychiatric illnesses represent a large portion of the neurotech market. What are the most promising next generation treatments? How will devices and diagnostics change the treatment landscape?

Through case studies, drug and device companies will discuss lessons learned and current issues in discovery, animal models, clinical trial design, regulatory hurdles, reimbursement challenges, financing and partnering. Regulatory and clinical experts will join the discussion to highlight changes at the FDA and strategies for changing current paradigms in CNS treatment development.